| Literature DB >> 34367515 |
Nor Hazliana Harun1, Nor Atiqah Rasdi1, Rabeta Mohd Salleh2, Sabreena Safuan1, Wan Amir Nizam Wan Ahmad1, Wan Ezumi Mohd Fuad1.
Abstract
<span class="Species">Syzygium polyanthum (Wight) Walp. var. polyanthum (serai kayu) leaves is a popular herb and widely used in traditional medicine. Despn>ite the ethnomedicinal benefits, very limited studies have researched on the <span class="Disease">toxicity of this plant. The aim of the present study was to investigate the potential effects of methanolic extract of Syzygium polyanthum (MESP) leaves via 28-day repeated oral dosing in Sprague Dawley rats. MESP leaves was administered at doses of 0 (control), 400, 1000 or 2000 mg/kg to an equal number of male and female rats (n = 10/group). Results obtained indicated that MESP did not affect the general conditions (body weight, feed intake and oestrous cycle) and apparent behavioural changes of the rats. Biochemical parameters revealed a slight significant variation in the aspartate aminotransferase (AST) level between the male rats treated with the lowest and highest doses of MESP, but these findings were both statistically insignificant when compared to the control group. The liver of the males (dose 1000 and 2000 mg/kg/day) also exhibited histoarchitectural defects on the hepatocytes and cytoplasm when compared to those of the control group. In contrast, female rats did not encounter any significant findings in all parameters tested. In conclusion, this study suggests that the MESP leaves might exhibit sex-based variation effects and thus, the use of this extract particularly at higher doses should be thoroughly considered. © Penerbit Universiti Sains Malaysia, 2021.Entities:
Keywords: Dilatasi Sinusoid; Ekstrak Metanol; Ketoksikan Subakut; Methanolic Extract; Sinusoidal Dilatation; Subacute Toxicity; Syzygium polyanthum
Year: 2021 PMID: 34367515 PMCID: PMC8300944 DOI: 10.21315/tlsr2021.32.2.5
Source DB: PubMed Journal: Trop Life Sci Res ISSN: 1985-3718
Effect of MESP leaves onterminal clinical biochemistry of SD rats for subacute (28 days) toxicity study.
| Parameters | Group 1 (control) | Group 2 (400 mg/kg) | Group 3 (1000 mg/kg) | Group 4 (2000 mg/kg) | |
|---|---|---|---|---|---|
| Males | |||||
| Sodium (mmol/L) | 144.00 ± 0.77 | 144.00 ± 0.55 | 145.60 ± 0.81 | 144.20 ± 0.37 | n/s |
| Potassium (mmol/L) | 6.19 ± 0.33 | 6.01 ± 0.12 | 6.86 ± 0.69 | 6.86 ± 0.49 | n/s |
| Chloride (mmol/L) | 101.80 ± 0.37 | 100.80 ± 0.73 | 101.40 ± 1.21 | 101.20 ± 0.66 | n/s |
| Creatinine (umo/L) | 41.72 ± 1.65 | 45.76 ± 1.08 | 46.98 ± 1.64 | 44.02 ± 1.47 | n/s |
| BUN (mg/dL) | 22.00 ± 1.14 | 21.40 ± 1.12 | 22.80 ± 1.07 | 19.60 ± 1.40 | n/s |
| Total cholesterol (mmol/L) | 1.76 ± 0.04 | 1.68 ± 0.04 | 1.82 ± 0.09 | 1.62 ± 0.06 | n/s |
| HDL (mmol/L) | 0.90 ± 0.12 | 0.94 ± 0.10 | 0.98 ± 0.09 | 0.96 ± 0.05 | n/s |
| LDL (mmol/L) | 0.66 ± 0.12 | 0.54 ± 0.10 | 0.54 ± 0.09 | 0.46 ± 0.05 | n/s |
| Triglyceride (mmol/L) | 0.40 ± 0.06 | 0.44 ± 0.02 | 0.62 ± 0.12 | 0.40 ± 0.03 | n/s |
| Total protein (g/L) | 54.20 ± 1.83 | 55.40 ± 0.75 | 56.60 ± 1.21 | 54.00 ± 0.71 | n/s |
| Albumin (g/L) | 26.80 ± 0.37 | 26.40 ± 0.24 | 26.40 ± 0.51 | 25.40 ± 0.68 | n/s |
| Total bilirubin (umo/l) | 1.70 ± 0.00 | 1.70 ± 0.00 | 1.70 ± 0.00 | 1.70 ± 0.00 | n/s |
| AST (U/L) | 155.80 ± 24.07 | 107.40 ± 7.88 | 121.20 ± 3.89 | 194.60 ± 33.91 | |
| ALT (U/L) | 63.40 ± 6.52 | 59.00 ±1.26 | 63.80 ± 5.00 | 67.60 ± 12.03 | n/s |
| GGT (U/L) | 4.20 ± 0.20 | 4.00 ± 0.00 | 4.00 ± 0.00 | 4.00 ± 0.00 | n/s |
| ALP (U/L) | 204.00 ± 19.83 | 226.40 ± 10.64 | 251.60 ± 41.72 | 154.60 ± 18.62 | n/s |
| Calcium (mmol/L) | 2.24 ± 0.04 | 2.28 ± 0.02 | 2.56 ± 0.15 | 2.42 ± 0.06 | n/s |
| Phosphorus (nmol/L) | 3.30 ± 0.10 | 3.35 ± 0.13 | 3.60 ± 0.28 | 3.34 ± 0.15 | n/s |
| Females | |||||
| Sodium (mmol/L) | 139.80 ± 1.16 | 143.60 ± 0.51 | 141.60 ± 0.75 | 140.60 ± 1.29 | n/s |
| Potassium (mmol/L) | 6.94 ± 0.60 | 6.68 ± 0.90 | 6.22 ± 0.70 | 6.12 ± 0.76 | n/s |
| Chloride (mmol/L) | 96.60 ± 1.86 | 99.40 ± 1.33 | 99.60 ± 0.93 | 100.00 ± 1.05 | n/s |
| Creatinine (umo/L) | 48.58 ± 1.99 | 49.82 ± 1.39 | 47.18 ± 2.27 | 49.44 ± 1.93 | n/s |
| BUN (mg/dL) | 23.80 ± 3.14 | 23.40 ± 1.81 | 22.00 ± 2.37 | 21.00 ± 1.70 | n/s |
| Total cholesterol (mmol/L) | 2.10 ± 0.10 | 2.02 ± 0.10 | 2.10 ± 0.19 | 1.88 ± 0.12 | n/s |
| HDL (mmol/L) | 1.40 ± 0.08 | 1.34 ± 0.10 | 1.38 ± 0.10 | 1.24 ± 0.09 | n/s |
| LDL (mmol/L) | 0.46 ± 0.07 | 0.46 ± 0.05 | 0.46 ± 0.09 | 0.42 ± 0.05 | n/s |
| Triglyceride (mmol/L) | 0.46 ± 0.04 | 0.50 ± 0.08 | 0.50 ± 0.06 | 0.42 ± 0.06 | n/s |
| Total protein (g/L) | 61.40 ± 0.81 | 60.60 ± 0.81 | 61.80 ± 2.24 | 62.00 ± 0.63 | n/s |
| Albumin (g/L) | 29.00 ± 0.05 | 28.00 ± 0.55 | 27.80 ± 0.73 | 27.00 ± 0.71 | n/s |
| Total bilirubin (umo/l) | 1.70 ± 0.00 | 1.70 ± 0.00 | 2.04 ± 0.34 | 2.04 ± 0.34 | n/s |
| AST (U/L) | 119.80 ± 5.25 | 136.00 ± 4.88 | 121.80 ± 5.12 | 171.00 ± 31.85 | n/s |
| ALT (U/L) | 50.20 ± 3.38 | 59.40 ± 6.14 | 52.40 ± 4.62 | 64.40 ± 3.64 | n/s |
| GGT (U/L) | 4.00 ± 0.00 | 4.00 ± 0.00 | 4.40 ± 0.40 | 4.00 ± 0.00 | n/s |
| ALP (U/L) | 162.60 ± 22.48 | 194.00 ± 44.26 | 161.60 ± 20.92 | 129.20 ± 15.05 | n/s |
| Calcium (mmol/L) | 2.34 ± 0.04 | 2.42 ± 0.08 | 2.40 ± 0.03 | 2.46 ± 0.04 | n/s |
| Phosphorus (nmol/L) | 3.90 ± 0.90 | 2.86 ± 0.27 | 2.66 ± 0.24 | 2.64 ± 0.16 | n/s |
Note: Data are expressed as mean ± SEM. n/s = Statistically not significant.
p < 0.05 when compared between Group 2 (400 mg/kg) and Group 4 (2000 mg/kg) but n/s (p > 0.05) with the control group.
Effect of MESP leaves on relative organ weights of SD rats for subacute (28 days) toxicity study.
| Parameters (g/100g) | Group 1 (control) | Group 2 (400 mg/kg) | Group 3 (1000 mg/kg) | Group 4 (2000 mg/kg) | |
|---|---|---|---|---|---|
| Males | |||||
| Brain | 0.71 ± 0.03 | 0.69 ± 0.02 | 0.68 ± 0.01 | 0.73 ± 0.01 | n/s |
| Heart | 0.34 ± 0.01 | 0.34 ± 0.01 | 0.36 ± 0.02 | 0.34 ± 0.01 | n/s |
| Lung (R) | 0.29 ± 0.01 | 0.31 ± 0.02 | 0.30 ± 0.01 | 0.32 ± 0.00 | n/s |
| Lung (L) | 0.15 ± 0.00 | 0.17 ± 0.01 | 0.17 ± 0.01 | 0.17 ± 0.00 | n/s |
| Liver | 3.25 ± 0.07 | 3.29 ± 0.06 | 3.26 ± 0.11 | 3.08 ± 0.04 | n/s |
| Spleen | 0.29 ± 0.02 | 0.29 ± 0.01 | 0.28 ± 0.01 | 0.29 ± 0.02 | n/s |
| Kidney (R) | 0.36 ± 0.02 | 0.35 ± 0.01 | 0.37 ± 0.03 | 0.35 ± 0.01 | n/s |
| Kidney (L) | 0.35 ± 0.02 | 0.31 ± 0.03 | 0.35 ± 0.02 | 0.35 ± 0.02 | n/s |
| Adrenal gland (R) | 0.01 ± 0.00 | 0.02 ± 0.01 | 0.01 ± 0.00 | 0.01 ± 0.00 | n/s |
| Adrenal gland (L) | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.00 | n/s |
| Stomach | 1.20 ± 0.14 | 1.28 ± 0.32 | 1.22 ± 0.27 | 1.06 ± 0.11 | n/s |
| Intestines | 7.32 ± 0.58 | 6.39 ± 0.28 | 6.93 ± 0.11 | 6.69 ± 0.17 | n/s |
| Bladder | 0.04 ± 0.00 | 0.03 ± 0.00 | 0.04 ± 0.01 | 0.04 ± 0.00 | n/s |
| Seminal vesicle (R) | 0.10 ± 0.01 | 0.12 ± 0.03 | 0.13 ± 0.01 | 0.11 ± 0.01 | n/s |
| Seminal vesicle (L) | 0.15 ± 0.02 | 0.13 ± 0.02 | 0.14 ± 0.02 | 0.11 ± 0.02 | n/s |
| Prostate gland (R) | 0.09 ± 0.01 | 0.09 ± 0.00 | 0.08 ± 0.00 | 0.09 ± 0.00 | n/s |
| Prostate gland (L) | 0.08 ± 0.00 | 0.09 ± 0.00 | 0.08 ± 0.00 | 0.09 ± 0.01 | n/s |
| Testis(R) | 0.52 ± 0.07 | 0.58 ± 0.01 | 0.57 ± 0.03 | 0.59 ± 0.01 | n/s |
| Testis (L) | 0.60 ± 0.01 | 0.58 ± 0.01 | 0.58 ± 0.04 | 0.59 ± 0.02 | n/s |
| Epididymis and Vas deferens (R) | 0.10 ± 0.00 | 0.17 ± 0.07 | 0.11 ± 0.01 | 0.11 ± 0.01 | n/s |
| Epididymis and Vas deferens (L) | 0.10 ± 0.00 | 0.10 ± 0.01 | 0.11 ± 0.00 | 0.11 ± 0.01 | n/s |
| Brain | 0.85 ± 0.02 | 0.86 ± 0.02 | 0.82 ± 0.04 | 0.85 ± 0.03 | n/s |
| Heart | 0.36 ± 0.01 | 0.35 ± 0.01 | 0.38 ± 0.00 | 0.36 ± 0.00 | n/s |
| Lung (R) | 0.26 ± 0.03 | 0.36 ± 0.09 | 0.33 ± 0.03 | 0.37 ± 0.01 | n/s |
| Lung (L) | 0.31 ± 0.07 | 0.27 ± 0.03 | 0.26 ± 0.06 | 0.19 ± 0.01 | n/s |
| Liver | 3.67 ± 0.12 | 3.67 ± 0.12 | 3.61 ± 0.12 | 3.39 ± 0.08 | n/s |
| Kidney (R) | 0.39 ± 0.01 | 0.37 ± 0.01 | 0.37 ± 0.01 | 0.38 ± 0.01 | n/s |
| Kidney (L) | 0.38 ± 0.01 | 0.36 ± 0.01 | 0.35 ± 0.01 | 0.36 ± 0.01 | n/s |
| Adrenal gland (R) | 0.02 ± 0.00 | 0.02 ± 0.00 | 0.02 ± 0.00 | 0.02 ± 0.00 | n/s |
| Adrenal gland (L) | 0.02 ± 0.00 | 0.02 ± 0.00 | 0.02 ± 0.00 | 0.02 ± 0.00 | n/s |
| Spleen | 0.32 ± 0.03 | 0.35 ± 0.01 | 0.31 ± 0.01 | 0.32 ± 0.01 | n/s |
| Stomach | 1.22 ± 0.19 | 1.42 ± 0.21 | 1.27 ± 0.25 | 0.85 ± 0.05 | n/s |
| Intestine | 7.88 ± 0.65 | 7.24 ± 0.42 | 7.00 ± 0.54 | 6.88 ± 0.33 | n/s |
| Bladder | 0.04 ± 0.00 | 0.04 ± 0.00 | 0.04 ± 0.00 | 0.04 ± 0.00 | n/s |
| Uterus | 0.25 ± 0.02 | 0.27 ± 0.02 | 0.24 ± 0.02 | 0.22 ± 0.02 | n/s |
| Fallopian tube (R) | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.0 | n/s |
| Fallopian tube (L) | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.00 | n/s |
| Ovary (R) | 0.02 ± 0.00 | 0.02 ±0.00 | 0.02 ± 0.00 | 0.02 ± 0.00 | n/s |
| Ovary (L) | 0.02 ± 0.00 | 0.02 ± 0.00 | 0.02 ± 0.00 | 0.02 ± 0.00 | n/s |
Note: Data are expressed as mean ± SEM. n/s = statistically not significant.
Figure 1Photomicrograph showing the histological sections of liver tissue of male rats (20x magnification). (A) Group 1 (control-DW), (B) Group 2 (MESP 400 mg/kg), (C) Group 3 (MESP 1000 mg/kg), (D) Group 4 (MESP 2000 mg/kg) (*: Central vein; □: Denudation of epithelial lining; → : Hepatocyte degeneration; ➡ : Sinusoidal dilatation)